German drugmaker Boehringer Ingelheim is investing €120 million in an upgrade and expansion of its facility in Koropi, Greece, that will increase the company's capacity to produce existing and new medicines. Main disease areas, Boehringer said, include cardio-renal-metabolic (CRM) diseases, mental health, and pulmonary fibrosis.